NCT00006022View on ClinicalTrials.gov

Interleukin-2 Plus Bryostatin 1 in Treating Patients With Melanoma or Kidney Cancer

PHASE1CompletedINTERVENTIONAL
Enrollment

17

Participants

Timeline

Start Date

September 30, 2000

Primary Completion Date

October 31, 2003

Study Completion Date

January 31, 2004

Conditions
Kidney CancerMelanoma (Skin)
Interventions
BIOLOGICAL

aldesleukin

DRUG

bryostatin 1

Trial Locations (2)

23219

Massey Cancer Center, Richmond

03756-0002

Norris Cotton Cancer Center, Lebanon

All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

lead

Virginia Commonwealth University

OTHER

NCT00006022 - Interleukin-2 Plus Bryostatin 1 in Treating Patients With Melanoma or Kidney Cancer | Biotech Hunter | Biotech Hunter